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Abstract
Background: Insulin dependent (i.e., "type 1") diabetes mellitus (T1DM) is considered to be a T
cell mediated disease in which TH1 and Tc autoreactive cells attack the pancreatic islets. Among the
beta-cell antigens implicated in T1DM, glutamic acid decarboxylase (GAD) 65 appears to play a key
role in the development of T1DM in humans as well as in non-obese diabetic (NOD) mice, the
experimental model for this disease. It has been shown that shifting the immune response to this
antigen from TH1 towards TH2, via the administration of GAD65 peptides to young NOD mice,
can suppress the progression to overt T1DM. Accordingly, various protocols of "peptide
immunotherapy" of T1DM are under investigation. However, in mice with experimental
autoimmune encephalomyelitis (EAE), another autoimmune TH1 mediated disease that mimics
human multiple sclerosis, anaphylactic shock can occur when the mice are challenged with certain
myelin self peptides that initially were administered with adjuvant to induce the disease.
Results: Here we show that NOD mice, that spontaneously develop T1DM, can develop fatal
anaphylactic reactions upon challenge with preparations of immunodominant GAD65 self peptides
after immunization with these peptides to modify the development of T1DM.
Conclusions: These findings document severe anaphylaxis to self peptide preparations used in an
attempt to devise immunotherapy for a spontaneous autoimmune disease. Taken together with the
findings in EAE, these results suggest that peptide therapies designed to induce a TH1 to TH2 shift
carry a risk for the development of anaphylactic reactivity to the therapeutic peptides.
Background
Type 1 diabetes mellitus (T1DM) is a T cell-mediated au-
toimmune disease characterized by lymphocytic infiltra-
tion of the pancreatic islets of Langerhans with
subsequent destruction of the insulin-producing beta cells
[1]. Non-obese diabetic (NOD) female mice, a murine
model for T1DM, spontaneously develop diabetes by 30
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weeks-of-age, with infiltrating cells appearing around the
pancreatic islets as early as at 3–4 weeks-of-age [2].
T1DM susceptibility in the NOD mouse is linked to I-Ag7,
the murine MHC class II gene that encodes a histidine at
position 56 and a serine at position 57 in the β chain, in
place of the more frequent proline 56β and aspartic acid
57β [3]. The development of diabetes is prevented in
NOD.PD mice (which are NOD mice with I-Ag7) that car-
ry a β chain transgene with site-specific mutations that re-
store proline and aspartic acid at positions 56β and 57β,
respectively [4]. Furthermore, because of the two amino
acid changes in the additional (transgenic) MHC class II
allele β chain in NOD.PD mice, NOD.PD mice recognize
three additional peptide epitopes in the glutamic acid de-
carboxylase 65 (GAD65) autoantigen [5].
Among beta-cell autoantigens, GAD65 is an important in-
itial target of the immune response that results in beta-cell
destruction and diabetes, in both humans and NOD mice
[6–9]. While both humoral and cellular responses to
GAD65 occur as early as 4 weeks of age in NOD mice [8],
there is considerable evidence that beta-cell-specific TH1
cells are the effectors of T1DM, whereas TH2 cells appear
to have a protective role [10]. Accordingly, a shift of the
autoimmune response from TH1 to TH2 predominance
has represented a promising strategy for prevention of di-
abetes and other TH1-mediated autoimmune diseases.
For example, administration of GAD65 to young NOD
mice has been shown to prevent insulitis and diabetes
[8,9], apparently via induction of CD4+ regulatory T cells
with a TH2 phenotype [10]. Similarly, treatment with im-
munodominant peptides of myelin can prevent or reverse
experimental autoimmune encephalomyelitis (EAE), a
TH1-associated inducible "autoimmune" disorder that is
widely used as a model for human multiple sclerosis [11–
13].
Unfortunately, recent work indicates that the application
of strategies to shift autoimmune responses from TH1 to
TH2 predominance is not without risk. Thus, some of us
recently showed that administration of two self peptides
that can induce EAE, myelin proteolipid protein peptide
139 to 151 (PLP139-151) or myelin oligodendrocyte glyc-
oprotein peptide 35–55 (MOG35-55), can result in severe
anaphylactic reactions [14]. This result clearly indicated
that severe allergic reactions to self peptides can occur in
mice that have been induced to express pathology (i.e.,
EAE) related to "autoimmunity" to these peptides. How-
ever, it was initially unclear whether anaphylactic reactiv-
ity also could be elicited to self peptides that have been
implicated in the development of a spontaneous autoim-
mune disorder.
In the present study, we show that anti-peptide autoanti-
bodies and fatal anaphylactic reactions can be elicited by
immunodominant GAD65 peptides in NOD mice that
have been injected with these peptides intraperitoneally
in incomplete Freund's adjuvant (IFA), as part of an at-
tempt to induce "tolerance" and prevent the spontaneous
development of T1DM. Moreover, while this manuscript
was in review, Liu and colleagues reported that anti-pep-
tide autoantibodies and fatal anaphylaxis can be induced
in NOD mice that have been immunized with insulin B
chain peptides B:9–23 or B:13–23 [15]. However, in the
Liu et al. study, the peptides were administered subcutane-
ously in saline without adjuvant. As reviewed in Liu et al.,
[15] several lines of evidence indicate that amino acids 9–
23 of the insulin B chain also represent a major target of
anti-islet autoimmunity in T1DM. Taken together with
the findings reported herein, this work indicates that ana-
phylactic reactions can be elicited in mice that have been
immunized with pancreatic islet-associated self-peptides
that also represent significant targets of autoimmunity in
T1DM.
Results
Anaphylactic responses to GAD65 and PD peptides
In an attempt to induce a TH2 shift, [19,20] 8 to 9 week
old female NOD mice (I-Ag7) were immunized by 3 week-
ly i.p. injections of the immunodominant G7 peptides
(GAD 206–226/217–236/286–300) or of the additional
GAD65 peptides identified in NOD.PD mice (I-ANOD/PD)
(GAD 333–345/K458-470R) in IFA [5]. As noted in the
background section, PD peptides are not immunodomi-
nant in NOD mice. Indeed, we originally included the
PD-immunized group because PD peptides are the immu-
nodominant epitopes that are presented in transgenic
NOD.PD mice that do not get diabetes [4,5]. Because of
their unknown, and potentially even protective, role in
the diabetes-resistant NOD.PD strain, we felt that it was
important to assess whether, through a peptide therapy
regimen, PD peptides might be able to protect against di-
abetes by shifting TH1 to TH2 responses in NOD mice. As
our study unfolded, and we found that G7 peptide thera-
py induced anaphylactic reactivity in NOD mice, we felt
that it was important to evaluate whether PD peptides
might also induce allergic responses in the NOD strain.
As demonstrated in our study, immunization of NOD
mice with PD peptides can induce both a specific IgG1 re-
sponse and also anaphylactic reactivity. On the other
hand, as might be predicted, PD peptides induced a less
robust IgG1 response (Figure 2) and also a lower inci-
dence and severity of anaphylaxis (see Table 1 and Figure
1) when injected into NOD mice than did G7 peptides. In
an attempt to induce anaphylactic reactivity to peptides
known to induce TH2 responses associated with allergic
reactions, NOD mice were immunized using the sameBMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/2
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Figure 1
Challenge with G7 or PD GAD65 peptides caused anaphylactic shock. NOD mice were not injected ("none") or 
received 3 weekly i.p. injections with saline (as a control) or the indicated peptide preparations in IFA, and, except for the 
None/None group, were challenged with saline or peptides in saline i.p. 4 weeks after the last immunization/injection (see 
Methods). IgE-mediated passive systemic anaphylaxis was induced in mice that had been sensitized with an i.p. injection of anti-
DNP IgE and then challenged i.v. 24 h later with DNP-HSA. Body temperature was measured at 5 minute intervals after chal-
lenge for 30 minutes or until death. Data are shown as mean +/- s. e. m. (A) Data for all mice, including those that gave no 
detectable anaphylactic response (i.e., temperature change of <1C° and no clinical signs of anaphylaxis). *, **, **** P < 0.05, 
0.01, or 0.0001 vs any negative control group (i.e., None/None, Saline-IFA/Saline, None/G7 peptides) by ANOVA. (B) Data for 
mice that exhibited anaphylaxis. ***, ****, n.s., P < 0.001, 0.0001, or not significant (P > 0.05) vs G7 Peptides/G7 Peptides.
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Figure 2
Peptide specific IgG1 and IgG2a antibodies in NOD mice immunized with G7 (A), PD (B), or HEL/OVA (C) 
peptides. Serum was collected 2–3 days before challenge with G7, PD, HEL/OVA or saline. IgG1 and IgG2a antibody 
responses specific for the G7, PD or HEL/OVA peptide epitopes were analyzed by ELISA. Each mouse was tested individually 
at a serum dilution of 1:20,000 for IgG1, and 1:25 for IgG2a for mice immunized against G7 peptides and 1:500 for IgG1 and 
1:200 for IgG2a for mice immunized against PD or HEL/OVA peptides. Data are shown as mean +/- s. e. m. "Saline" = mice 
injected with saline/IFA; none = non-injected naïve mice.
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protocol with hen egg lysozyme and ovalbumin peptides
(HEL 81–96, OVA 323–339) [21–23]. As a negative con-
trol, NOD mice received 3 weekly injections of saline
emulsified in IFA. Four weeks after the last of the 3 i.p. in-
jections of peptides/IFA or saline/IFA, mice injected with
peptides/IFA were challenged i.p. with the same peptides
used for the immunizations dissolved in saline, whereas
mice that had been injected with saline/IFA were chal-
lenged with saline alone. By the day of challenge, 10–15%
of all mice had developed diabetes, with the exception of
the mice in the saline group (0%).
All of the mice challenged with G7 peptides developed se-
vere anaphylactic shock (100%; 14/14), with the majority
of them dying within 30 minutes after the injection (86%;
12/14) (Table 1). In addition to the classical signs of ana-
phylaxis, such as reddening of the skin, prostration and
respiratory impairment, the mice underwent a dramatic
drop in body temperature (Fig. 1), which confirmed the
presence of anaphylactic shock. Moreover, the death rate
from anaphylaxis was substantially higher than in any
other group in which anaphylaxis occurred (Table 1).
On the other hand, the clinical and physiological features
of anaphylaxis elicited by the G7 peptides were similar to
those observed in age- and gender-matched NOD mice
undergoing IgE-mediated passive systemic anaphylaxis
(Fig. 1). Although the death rate was significantly higher
in the G7 challenged NOD group (86%; 12/14) compared
to the IgE-sensitized, DNP-HSA challenged group (none)
(P = < 0.0001 by Fisher's exact test, Table 1), those mice in
either group that developed anaphylaxis exhibited quite
similar drops in body temperature (Fig. 1B). Similarly,
while the group of mice that was challenged with G7 pep-
tides exhibited a higher incidence of anaphylactic re-
sponses than did the group challenged with HEL/OVA
peptides (Table 1), the temperature changes (Fig. 1B) and
death rates (Table 1) in mice that did develop a reaction
were quite similar.
None of the naïve age/gender-matched NOD mice (these
mice received no injection prior to challenge) that were
challenged with G7 peptides showed any signs of anaph-
ylaxis (0/9; P < 0.0001 by Fisher's exact test for compari-
son vs. G7 immunized, G7 challenged mice) (Table 1, Fig.
1). This result indicates that priming of these mice with
G7 peptides is required for the elicitation of the allergic
response.
Of the mice immunized with the PD peptides, that are not
immunodominant in NOD mice, 43% (3/7) developed
anaphylactic shock at the time of challenge with PD pep-
tides (Table 1). Thus, the incidence of anaphylactic shock
in mice immunized and challenged with PD peptides was
significantly lower than that in mice immunized and chal-
lenged with immunodominant G7 peptides (P = 0.0058
by Fisher's exact test). Moreover, of those PD-immunized,
PD-challenged mice that did exhibit an anaphylactic reac-
tion, the drop in temperature was less sustained than that
in those mice in the other groups that exhibited anaphy-
laxis (Fig. 1B) and only 1 of these mice died (33%) (Table
1). In accord with these results, immunization of the
NOD mice with PD peptides produced a less robust spe-
cific IgG1 antibody response than did immunization with
the immunodominant G7 peptides (see below). As ex-
pected, none of the mice immunized with saline/IFA
Table 1: 
Immunizationa Challengeb
Number of Mice with Anaphylaxis
Temperature Decrease ≥ 1 °C Death (all mice) Death (in mice with anaphylaxis)
G7 peptides G7 peptides 14/14 (100%) * 12/14 (86%)** 12/14 (86%)***
PD peptides PD peptides 3/7 (43%) † 1/7 (14%) 1/3 (33%)
HEL/OVA HEL/OVA 5/12 (42%) ‡ 4/12 (33%) ‡‡ 4/5 (80%) ‡‡‡
Saline Saline 0/13 (0%) 0/13 (0%) -
None (no injection) None (no injection) 0/9 (0%) 0/9 (0%) -
No injection G7 peptides 0/9 (0%) 0/9 (0%) -
Passive Systemic IgE-induced Anaphylaxis
IgE anti-DNP DNP-HSA 10/10 (100%)# 0/10 (0%) 0/10 (0%)
a Immunizations in IFA b Challenge in 0.9% NaCl (saline) * P = 0.0058 vs. PD challenged, P = 0.0012 vs. HEL/OVA challenged, P < 0.0001 vs. G7 
challenged non-immunized mice, saline challenged or "none" groups; † P = 0.031 vs saline challenged; ‡ P < 0.05 vs G7 challenged non-immunized 
mice, saline challenged or "none" groups; # P = 0.0147 vs PD challenged, P = 0.0053 vs HEL/OVA, P < 0.0001 vs G7 challenged non-immunized 
mice, saline challenged or "none" groups.; ** P = 0.0138 vs. HEL/OVA challenged, P < 0.0001 vs DNP-HSA challenged; ‡‡ P = 0.048 vs saline chal-
lenged; *** P < 0.0001 vs DNP-HSA challenged; ‡‡‡ P = 0.0037 vs DNP-HSA challenged; all other comparisons are P > 0.05 (Fisher exact test).BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/2
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alone developed anaphylaxis upon i.p. challenge with sa-
line (Table 1, Fig. 1).
Notably, in the mice immunized with G7, PD or HEL/
OVA emulsified in IFA, anaphylactic responses were also
provoked by the third i.p. immunization with peptides
(10/12 in the G7 group; 3/4 for PD, 3/10 for HEL/OVA).
However, these anaphylactic responses were less severe
than those induced by subsequent peptide challenge of
the same mice, with a less dramatic drop in body temper-
ature (data not shown) and no deaths. Finally, although
the numbers of mice that had developed diabetes by the
day of peptide challenge in each of the immunized groups
was small (10–15%), there were no statistically significant
differences in the incidence of anaphylactic reactions in
these mice vs. mice that were normoglycemic at the time
of peptide challenge.
IgG1, IgG2a and IgE responses
Antibody responses were analyzed by ELISA in serum ob-
tained 2 to 3 days before the 4 week challenge with pep-
tides or saline. Mice immunized with the G7 peptides had
high IgG titers against the G7 peptides, with levels of IgG1
being significantly higher than those of IgG2a (P < 0.0001
by Mann-Whitney U test, 2-tailed; Figure 2A). Anti-G7 IgG
antibodies generally were not detectable in the other
groups (PD- or HEL/OVA- immunized, or IFA alone) or in
the non-injected (naïve) mice. The two exceptions were a
single non-immunized mouse with anti-G7 IgG1 anti-
bodies (at a serum concentration of 90 µg/ml), and one
mouse immunized with HEL/OVA with anti-G7 IgG2a
antibodies (at a serum concentration of 492 ng/ml). Anti-
peptide IgG1 and IgG2a antibodies also were detected in
PD- (Figure 2B) and HEL/OVA- (Figure 2C) immunized
mice, although the magnitude of the antibody responses
to these peptides (especially the IgG1 response) were sub-
stantially less than those to the G7 peptides.
Total IgE concentrations were slightly, but significantly,
higher in the peptide-immunized groups (G7, PD, or
HEL/OVA) compared to those in mice injected with IFA
and saline alone (Figure 3). However, the serum concen-
trations of total IgE were very similar in the mice that had
been immunized with G7, PD or HEL/OVA peptides (Fig-
ure 3).
Discussion
This study clearly demonstrates that i.p. immunization of
NOD mice with preparations of GAD65 self peptides in
IFA can cause a marked shift towards a TH2 like response,
as reflected by high levels of IgG1. Similarly, Liu et al. re-
cently demonstrated that strong IgG1 responses can be in-
duced in NOD mice that have been immunized
subcutaneously with insulin B chain peptides
administered in physiological saline [15]. However, both
studies showed that anaphylaxis can be induced in such
mice upon subsequent re-challenge with preparations of
the peptides used for immunization [15]. Moreover, the
anaphylactic reactions in mice that had been immunized
and challenged with G7 peptides were severe, with reduc-
tions in body temperature that were very similar to those
observed in mice exhibiting IgE-dependent passive sys-
temic anaphylaxis and with a very high fatality rate (12/14
mice, or 86%). Anaphylaxis also developed in some NOD
mice that had been immunized and challenged with prep-
arations of PD peptides (that are not immunodominant
in NOD mice), although both the drop in body tempera-
ture and the death rate in these mice were significantly less
than those observed in the mice immunized and chal-
lenged with G7 peptides.
There were both similarities and differences between our
findings in the NOD mouse model of T1DM and those in
the EAE model [14]. Expression of EAE requires specific
immunization with self peptides (e.g., PLP 139–151 or
MOG35-55), and these peptides generally are adminis-
tered in complete Freund's adjuvant (CFA). By contrast,
T1DM develops spontaneously in NOD mice. On the oth-
er hand, induction of anaphylactic reactivity in NOD mice
appeared to require immunization of the mice with
GAD65 peptides (in this model, in IFA), as naïve NOD
mice challenged with G7 peptides exhibited no detectible
reactions, and none of them died (Table 1). Thus, in both
the EAE model [14] and the NOD T1DM model (this
study, and that of Liu et al., [15]) some form of artificial
Figure 3
Immunization with G7, PD, or HEL/OVA peptides 
induced modest changes in total IgE. Total IgE serum 
concentrations were measured at a dilution of 1:100 by sand-
wich ELISA. Data are shown as mean +/- s. e. m. * = P < 0.05 
vs. levels in saline-treated mice.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/2
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"immunization" with a self peptide preparation appears
to be required for the development of anaphylactic reac-
tivity to "self". This of course is not a surprising result. In-
deed, it is challenging to conceive of any possible selective
advantage that would be conferred by a propensity to de-
velop, under "natural" conditions, potentially fatal aller-
gic reactions to components of self. It remains to be
determined whether self peptide immunization protocols
that induce anaphylactic reactivity do so simply because
of the manner in which they present large amounts of self
peptides to the immune system, or because of other fac-
tors, such as the presence in the peptide preparations of
aggregates or other components beside self peptide
monomers.
Whatever the underlying reason(s) for the development of
anaphylactic reactivity to these self peptide preparations,
in both the EAE and the NOD T1DM models, anaphylac-
tic reactions occurred in mice that had developed strong
IgG1 responses to the relevant self peptides, with only
modest changes in total IgE levels. In humans, antigen-
specific anaphylactic reactivity is thought to be mediated
solely (or primarily) by IgE antibodies, whereas it has long
been known that either IgE or IgG1 antibodies can medi-
ate anaphylaxis in mice (reviewed in [14,15] and [17]).
However, it has been reported that IgG1-dependent ana-
phylaxis in the mouse is associated with substantially less
histological evidence of mast cell degranulation than is
observed in IgE-dependent anaphylaxis in that species
[17]. In neither of the models of "autoimmunity" that we
have studied (i.e., EAE, T1DM in NOD mice) was anaph-
ylaxis associated with histological evidence of substantial
mast cell degranulation [14] (data not shown). Taken to-
gether, these findings suggest that IgG1 antibodies con-
tribute importantly to the development of anaphylaxis in
both of these models. On the other hand, we can not rule
out some role for IgE antibodies in these reactions.
Indeed, Liu et al. [15] found that, in NOD mice that had
been immunized with peptide B:9–23, treatment with
both anti FcγRII/RIII and anti-IgE monoclonal antibodies
was required to prevent anaphylaxis upon challenge with
the peptide. Interestingly, however, Liu et al. [15] did not
detect IgE antibodies to B:9–23 or B:13–23 in the serum
of their NOD mice. By contrast, mice that had been im-
munized with B:9–23 peptide at 10 or 100 µg/dose exhib-
ited a robust and dose-dependent IgG1 antibody response
to the peptide [15]. Thus, in both B:9–23 peptide-associ-
ated anaphylaxis (Liu et al. [15]) and GAD65 peptide-as-
sociated anaphylaxis (our study), anti-peptide IgG1
antibodies contribute to the response. However, IgE anti-
bodies also appear to contribute to anaphylaxis to B:9–23
peptides [15], and may also be involved in our model.
One point not yet clarified by the comparison of the
present results, those of Liu et al. [15], and those of Pedotti
et al.[14] is whether the influence of thymic expression of
the self peptide on the propensity to develop anaphylactic
reactivity differs in the EAE and NOD T1DM models. In
the study by Pedotti et al. [14], it was noted that the two
self peptides that induced anaphylactic reactivity, MOG
35–55 and PLP139–151, are not expressed in the thymus,
whereas the two peptides tested that did not induce ana-
phylactic reactivity, PLPp 178–191 and MBPAC1–11, are
expressed at that site. However, both GAD65 and GAD67
mRNA can be detected in the thymic medullary epithelial
cells in mice [24]. Thus, despite thymic expression of
GAD65 and GAD67 at the level of mRNA, NOD mice
spontaneously develop autoreactivity to these islet (and
brain) expressed proteins, and re-challenge of mice that
have been immunized with peptides from GAD65 results
in severe anaphylactic reactions. On the other hand, ex-
pression of GAD65 or GAD67 protein in the thymus has
not yet been reported. Similarly, as reviewed in Liu et al.
[15], although several lines of evidence indicate that insu-
lin is present in the thymus of mice and humans, it is pos-
sible that the specific insulin peptides that induced
anaphylaxis in their study are not ordinarily present in
that site. As a result, it has not yet been demonstrated that
anaphylactic reactions can develop to self peptides that
are expressed in the thymus.
It should be emphasized that NOD mice have a partial de-
fect in thymic negative selection [25,26], a defect in FcγRI-
IB (that can negatively regulate anaphylactic reactions
[27,28]), and perhaps other genetic polymorphisms that
may result in immunological hyperresponsiveness. The
same is likely to be true in at least some patients with type
1 diabetes, and in patients in the pre-diabetic phase.
Therefore, because of the risk of induction of anaphylactic
sensitization, extreme caution needs to be used in devel-
oping any type of antigen-specific immunosuppressive
therapy for the prevention or treatment of T1DM. This
caution probably should be extended to all attempts to
shift immune responses to self or foreign antigens from a
TH1 to a TH2 response. Indeed, in a recent phase II clinical
trial, 9% of MS patients given an altered peptide ligand
(APL) of a myelin basic protein epitope developed imme-
diate hypersensitivity reactions after multiple injections of
the APL [29]. Thus, it would appear that great care must be
taken when injecting preparations of putative "tolero-
gens" in attempts to suppress TH1-mediated autoimmune
diseases.
Methods
Mice
Female NOD/LtJ mice (The Jackson Laboratory, Bar Har-
bor, ME), were maintained on Lab Diet 5K52 (Purina, St
Louis, MO), under filter-top barrier conditions. Mice wereBMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/2
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tested three times a week for glycosuria using Chemstrip
uGK (Roche Diagnostics, Indianapolis, IN), and consid-
ered diabetic when tested positive (glucose levels above
100 mg/dL), on three consecutive occasions.
Peptides
Three peptide pools consisted of: G7 (GAD 206–226,
GAD 217–236, GAD 286–300), PD (GAD K458-470R,
GAD 333–345), and hen egg lysozyme/ovalbumin (HEL/
OVA; HEL 81–96, OVA 323–339). All peptides were syn-
thesized by Research Genetics (Huntsville, AL) and were
confirmed > 90% pure by HPLC and Mass Spectrometry
analysis.
Immunizations
Mice (8–9 weeks old) received three weekly intraperito-
neal (i.p.) injections of 100 µl containing a mixture of 200
µg each of the G7 peptides, the PD peptides or the HEL/
OVA peptides, dissolved in 50 µl of sterile, pyrogen-free
0.9% NaCl ("saline") and emulsified in an equal volume
of incomplete Freund's adjuvant (IFA) (Difco Laborato-
ries, Detroit, MI). A peripheral blood sample was ob-
tained 2 to 3 days before challenge and was analyzed for
antibody response by ELISA. Mice were challenged four
weeks after the third immunization (at 15-16 weeks-of-
age) by i.p. injection of the same peptide pools (200 µg of
each peptide) dissolved in saline. Mice were observed for
30 minutes after challenge for signs of anaphylaxis, and
temperature was taken at intervals of 5 minutes. As nega-
tive control groups, mice were immunized with an emul-
sion of IFA and saline and challenged with saline, and age-
gender-matched non-immunized mice were challenged
with the G7 mixture (containing 200 µg of each peptide
in pool) dissolved in 50 µl of saline. As an additional con-
trol, temperature measurements were taken from unma-
nipulated (non-injected) naïve mice.
Passive systemic anaphylaxis
For passive systemic anaphylaxis, 15-week-old NOD mice
were injected i.p. with 20 µg anti-DNP-IgE (IgE hybrido-
ma = H1 DNP-ε-26) [16] dissolved in 200 µl HMEM (Gib-
co-BRL, Gaithersburg, MD) with PIPES buffer (0.47 g/l,
Sigma, St. Louis, MO). Twenty-four hours later, mice were
challenged intravenously (i.v.) with 200 µg DNP-HSA
(Sigma) dissolved in 200 µl saline [17].
Temperature measurement
Rectal temperatures were taken using Physitemp (Clifton,
NJ). Basal temperatures were recorded before challenge,
and temperature readings were taken at 5 minute intervals
until death from anaphylaxis or 30 minutes post injec-
tion, whichever occurred first. Temperature measure-
ments were performed in a "blinded" fashion.
IgG1 and IgG2a antibody measurements
G7, PD and HEL/OVA peptide-specific IgG1 and IgG2a re-
sponses were measured in duplicate with mouse sera col-
lected 1 to 3 days before challenge. EIA/RIA 96-well plates
(Corning Incorporated, Acton, MA) were coated overnight
at 4°C with a 100 µl mixture of each peptide preparation
in a pool for a total peptide concentration of 30 µg/ml di-
luted in physiologic saline. After 3 washes with phos-
phate-buffered saline (PBS) and 0.05% Tween 20
(Sigma), plates were blocked with PBS plus 2% BSA (Sig-
ma), and 0.02% sodium azide (Sigma), for 2 hours at
room temperature (RT). Serum samples were diluted in
blocking buffer and incubated for two hours at RT. After 1
hr incubation at RT with 50 µl/well of biotinilated sec-
ondary antibodies, plates were developed with Eu-la-
belled Streptavidin (PerkinElmer Life Sciences, Boston,
MA) followed by Enhancement solution (PerkinElmer
Life Sciences) and read in a 1234 Delfia Fluorometer
(PerkinElmer Life Sciences). Serum Ig values were interpo-
lated from standard curves obtained by coating the plates
directly with purified IgG1 or IgG2a (PharMingen) at a
starting concentration of 500 ng/ml, according to the
manufacturer's instructions.
Total IgE antibody measurement
Total IgE was measured in duplicate with mouse serum at
1:100 dilution by sandwich ELISA (PharMingen) accord-
ing to the manufacturer's instructions [18].
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